Objective
Seven of the top 10 global medicines by spending are biotherapeutics drugs, and the market is growing at a CAGR of 10.1% to reach a value of $287 billion in 2020.
Challenges facing biotherapeutic manufacture are: i) Chromatographic purification, accounting for >50% of processing costs. This is important given the increasing price sensitivity of payers worldwide and serves as a limitation to the growth of the biosimilar industry; ii) Increasing diversity and complexity of biotherapeutics: ~70% of biopharma’s product pipeline are large complex proteins (e.g. bispecific antibodies, fusion proteins or viral vectors), which offer promising therapeutic opportunities, but cannot be manufactured cost effectively as they do not fit with current bioprocessing platform technologies; iii) Process flexibility: The rapidly evolving industry is moving to more flexible disposable formats to cope with uncertainty in drug development and varying market demand.
Puridify has developed an innovative bioprocessing platform technology, FibroSelect, a functionalised cellulose chromatography medium to enable high-productivity, product capture and purification that is economic to operate in a disposable manner.
FibroSelect addresses each point above by i) enabling cost reductions of up to 25% (potentially £700K - £2.7m per batch); ii) offering flexibility to design new bioprocessing platforms; iii) being a wholly disposable system where all purifying ligand is expended per-batch purification. It is innovation in the latter area that helps to drive costs down and increase productivity, as the requirement for cleaning columns and re-validating prior to purification of the next batch of biotherapeutic product is ameliorated. FibroSelect eases process constraints and enables flexibility through single-use processing opportunities thereby maximising facility utilisation as has been seen with the rapid growth in use of single-use technologies for manufacturing.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- engineering and technology environmental biotechnology bioremediation bioreactors
- engineering and technology chemical engineering separation technologies
- medical and health sciences clinical medicine oncology
- engineering and technology industrial biotechnology bioprocessing technologies fermentation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2016-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
SG1 2FX STEVENAGE
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.